Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13103767 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL31108103 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL22330323 | 0.82 | CHRNB2 (0.55) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL31108110 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL13757463 | 0.82 | CHRNB2 (0.51) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5043519 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL23231442 | 0.79 | CHRNB2 (0.57) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL26124529 | 0.79 | CHRNB2 (0.57) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL21521567 | 0.79 | CHRNB2 (0.57) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL22425334 | 0.78 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8153628-B2 | Pyrazolyl substituted xanthines | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-04-10 | — | — | US | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | PGXHEALTH, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-7618962-B2 | Pyrazolyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-11-17 | — | — | US | disclosed |
| US-7601723-B2 | Pyridyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120765-A1 | PYRAZOLYL SUBSTITUTED XANTHINES | ADORA2B, ADORA2A, ADORA3 | CHRNB2 435/4885CHRNA4 469/4885HDAC1 3806/4885 |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | CHRNB2 435/4885CHRNA4 469/4885HDAC1 3806/4885 |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | CHRNB2 333/4885CHRNA4 468/4885HDAC1 3747/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | CHRNB2 333/4885CHRNA4 468/4885HDAC1 3747/4885 |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADORA2B, GPR119, ADORA2A | CHRNB2 284/4885CHRNA4 513/4885HDAC1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.